- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection [url=]Man Fung Yuen[/url]1,∗,[url=]Correspondence information about the author Man Fung Yuen[/url]Email the author Man Fung Yuen
, [url=]Edward J. Gane[/url]2
, [url=]Dong Joon Kim[/url]3
, [url=]Frank Weilert[/url]4
, [url=]Henry Lik Yuen Chan[/url]5
, [url=]Jacob Lalezari[/url]6
, [url=]Seong Gyu Hwang[/url]7
, [url=]Tuan Nguyen[/url]8
, [url=]Osvaldo Flores[/url]9
, [url=]George Hartman[/url]10
, [url=]Sandy Liaw[/url]11
, [url=]Oliver Lenz[/url]12
, [url=]Thomas N. Kakuda[/url]13
, [url=]Willem Talloen[/url]14
, [url=]Christian Schwabe[/url]15
, [url=]Klaus Klumpp[/url]16
, [url=]Nathaniel Brown[/url]9
Open Access
PlumX Metrics
DOI: https://doi.org/10.1053/j.gastro.2018.12.023 |
Article Info
Background & AimsNVR 3-778 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that can inhibit HBV replication. We performed a proof-of-concept study to examine the safety, pharmacokinetics, and antiviral activity of NVR 3-778 in patients with chronic HBV infection.
MethodsWe performed a phase 1 study in 73 hepatitis B envelope antigen (HBeAg)-positive patients with chronic HBV infection without cirrhosis. In a 2-part study (part 1 in New Zealand and part 2 in Hong Kong, Singapore, Taiwan, Korea, and the United States), patients were randomly assigned to groups that were given oral NVR 3-778 (100 mg, 200 mg, or 400 mg daily or 600 mg or 1000 mg twice daily) or placebo for 4 weeks. Additional groups received combination treatment with pegylated interferon (pegIFN) and NVR 3-778 (600 mg twice daily) or pegIFN with placebo.
ResultsReductions in serum levels of HBV DNA and HBV RNA were observed in patients receiving ≥1200 mg/d NVR 3-778. The largest mean reduction in HBV DNA was observed in the group given NVR 3-778 plus pegIFN (1.97 log10 IU/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.43 log10 IU/mL and 1.06 log10 IU/mL, respectively). The mean reduction in HBV RNA was also greatest in the group given NVR 3-778 plus pegIFN (2.09 log10 copies/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.42 log10 copies/mL and 0.89 log10 copies/mL, respectively). There was no significant mean reduction in HBsAg during the 4-week treatment period. There were no discontinuations and no pattern of dose-related adverse effects with NVR 3-778.
ConclusionsIn a phase 1 study of HBeAg-positive patients with chronic HBV infection without cirrhosis, NVR 3-778 was well tolerated and demonstrated antiviral activity. The agent reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with pegIFN. The observed reductions in HBV RNA confirmed the novel mechanism of NVR 3-778. Clinicaltrials.gov no. NCT02112799 (single-center) and NCT02401737 (multicenter).
Keywords:Encapsidation, [url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=Capsid Inhibitor&code=ygast-site]Capsid Inhibitor[/url], [url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=Hepatitis B Treatment&code=ygast-site]Hepatitis B Treatment[/url], [url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=Clinical Trial&code=ygast-site]Clinical Trial[/url]
Abbreviations used in this paper:AE ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=adverse event&code=ygast-site]adverse event[/url]), ALT ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=alanine aminotransferase&code=ygast-site]alanine aminotransferase[/url]), BD ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=twice daily&code=ygast-site]twice daily[/url]), CAM ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=capsid assembly modulators&code=ygast-site]capsid assembly modulators[/url]), cccDNA ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=covalently closed circular DNA&code=ygast-site]covalently closed circular DNA[/url]), EC50 ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=median effective concentration&code=ygast-site]median effective concentration[/url]), HBc ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=HBV core protein&code=ygast-site]HBV core protein[/url]), HBcrAg ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=hepatitis B core-related antigen&code=ygast-site]hepatitis B core-related antigen[/url]), HBeAg ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=hepatitis B envelope antigen&code=ygast-site]hepatitis B envelope antigen[/url]), HBsAg ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=hepatitis B surface antigen&code=ygast-site]hepatitis B surface antigen[/url]), HBV ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=hepatitis B virus&code=ygast-site]hepatitis B virus[/url]), pegIFN ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=pegylated interferon&code=ygast-site]pegylated interferon[/url]), pgRNA ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=pregenomic RNA&code=ygast-site]pregenomic RNA[/url]), QD ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=once daily&code=ygast-site]once daily[/url]), SAE ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=serious adverse event&code=ygast-site]serious adverse event[/url]), TDF ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=tenofovir disoproxil fumarate&code=ygast-site]tenofovir disoproxil fumarate[/url]), ULN ([url=https://www.gastrojournal.org/action/doSearch?searchType=quick&occurrences=all<rlSrch=true&searchScope=fullSite&searchText=upper limit of normal&code=ygast-site]upper limit of normal[/url])
Conflicts of interest These authors disclose the following: Man Fung Yuen is an advisor for AbbVie, Arbutus, Arrowhead, Biocartis, Gilead Sciences, GlaxoSmithKline, Ionis, Roche, and Vir Biotechnology; and received speaker and grant supports from AbbVie, Arrowhead, Bristol Myers Squibb, Fujirebio, Gilead Sciences, Merck Sharp & Dohme, Novartis Pharmaceuticals, Sysmex. Henry Lik Yuen Chan is an advisor for AbbVie, Aptorum, Arbutus, Altimmune, Gilead, GRAIL, Intellia, Janssen, MedImmune, Roche, and Vir Biotechnology; and a speaker for AbbVie, Gilead, and Roche. George Hartman, Sandy Liaw, Klaus Klumpp, and Nathaniel Brown were employees of Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies. Osvaldo Flores was an employee of Novira Therapeutics Inc, part of the Janssen Pharmaceutical Companies, at the time that this study was undertaken, but is no longer employed by this company. Oliver Lenz and Willem Talloen are employees of Janssen Pharmaceutica NV. Thomas N. Kakuda is an employee of Janssen Biopharma, a Janssen Pharmaceutical Company, and holds stocks in Johnson & Johnson. The remaining authors disclose no conflicts.
Funding The multicenter phase 1b clinical trial reported here was supported by grants from Novira Therapeutics, the discoverer and developer of the investigational agent NVR 3-778.
|
|